ABAXIS INC
10-K405, EX-27.1, 2000-06-29
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ABAXIS INC, 10-K405, EX-23.1, 2000-06-29
Next: PIC GROWTH PORTFOLIO, NSAR-A, 2000-06-29



<TABLE> <S> <C>

<ARTICLE>  5
<LEGEND>   This schedule contains summary financial information extracted
           from the Balance Sheet and Statement of Operations included in the
           Company's Form 10-K for the fiscal year ended March 31, 2000 and is
           qualified in its entirety by reference to such Financial Statements.
</LEGEND>
<MULTIPLIER>1

<S>                                                 <C>
<FISCAL-YEAR-END>                                   MAR-31-2000
<PERIOD-START>                                      APR-01-1999
<PERIOD-END>                                        MAR-31-2000
<PERIOD-TYPE>                                       12-MOS
<CASH>                                                2,049,000
<SECURITIES>                                                  0
<RECEIVABLES>                                         5,566,000
<ALLOWANCES>                                            466,000
<INVENTORY>                                           2,725,000
<CURRENT-ASSETS>                                     10,002,000
<PP&E>                                               10,142,000
<DEPRECIATION>                                        6,201,000
<TOTAL-ASSETS>                                       14,098,000
<CURRENT-LIABILITIES>                                 5,983,000
<BONDS>                                                       0
                                         0
                                                   0
<COMMON>                                             68,005,000
<OTHER-SE>                                          (60,768,000)
<TOTAL-LIABILITY-AND-EQUITY>                         14,098,000
<SALES>                                              23,090,000
<TOTAL-REVENUES>                                     23,230,000
<CGS>                                                12,141,000
<TOTAL-COSTS>                                        12,141,000
<OTHER-EXPENSES>                                     11,707,000
<LOSS-PROVISION>                                              0
<INTEREST-EXPENSE>                                      170,000
<INCOME-PRETAX>                                        (577,000)
<INCOME-TAX>                                                  0
<INCOME-CONTINUING>                                    (577,000)
<DISCONTINUED>                                                0
<EXTRAORDINARY>                                               0
<CHANGES>                                                     0
<NET-INCOME>                                           (577,000)
<EPS-BASIC>                                             (0.05)
<EPS-DILUTED>                                             (0.05)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission